title: Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases.
abstract: In the past 15 years, more than 1,500 patients worldwide have received a hematopoietic stem cell transplant, mostly autologous, as treatment for a severe autoimmune disease (AD). A recent retrospective analysis of 900 patients showed that the majority had multiple sclerosis, systemic sclerosis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and juvenile idiopathic arthritis (JIA; n = 65) and idiopathic cytopenic purpura. An overall 85% 5-year survival and 43% progression-free survival was seen, with 100-day transplant-related mortality (TRM) ranging between 1% (RA) and 11% (SLE and JIA). Around 30% of patients in all disease subgroups had a complete response, despite full immune reconstitution. In many patients, morphological improvement was documented beyond any predicted known effects of intense immunosuppression alone. It is hoped that the results of three ongoing large prospective, randomized, controlled trials will allow modification of the protocols to reduce the high TRM, which relates to regimen intensity, age of patient, and comorbidity. Multipotent mesenchymal stromal cells (MSCs), including autologous MSCs, have recently been tested in various ADs, exploiting their immune-modulating properties and apparent low acute toxicity. Despite encouraging small phase I/II studies, no positive data from randomized, prospective studies are as yet available in the peer-reviewed literature.
authors.affiliation: Department of Rheumatology, Felix Platter Spital, University of Basel, Basel, Switzerland. alan.tyndall@fps-basel.ch
authors.forename: Alan
authors.initials: A
authors.lastname: Tyndall
mesh_terms: D000328:Adult; D001327:Autoimmune Diseases / Q000628:therapy*; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D010372:Pediatrics / Q000379:methods* / Q000639:trends; D012216:Rheumatic Diseases / Q000628:therapy*; D014182:Transplantation, Autologous / Q000379:methods* / Q000401:mortality